Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors.

This study aims to explore the efficacy and safety of mirabegron in treating irritative symptoms induced by intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) after transurethral resection of bladder tumors (TURBT).